Compare Citius Pharmaceuticals Inc (CTXR) vs Fox Corp Class B (FOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Fox Corp Class B — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Fox Corp Class B trades at $59.02 (market cap $24.97B). The key difference: Fox Corp Class B is far larger — about 1810.7× Citius Pharmaceuticals Inc's market cap, and Fox Corp Class B pays a 1.04% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Fox Corp Class B for 75 Days on average.
| CTXR | FOX | |
|---|---|---|
Market Cap | $13.79M | $24.97B |
Volume | 156,684 | 643,221 |
Sector | Health | Media |
52-Week High | $1.82 | $67.76 |
52-Week Low | $0.48 | $44.39 |
Typical Hold Time | 16 Days | 75 Days |
Enterprise Value | $3.96M | $28.33B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
FOX trades at $56.97, up 2.5% today, with a bearish technical signal but strong fundamentals including a P/E of 14.59 and net income margin of 9.84%. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight operational strength, while cash flow improved to $1.03B in 2025. The stock faces resistance near $57 with support at $55.
The outlook is mixed: analyst consensus targets $84.75 (49% upside) with 42% buy ratings, but technical indicators and projected 2026 earnings decline pose risks. Key opportunities include valuation discount and dividend yield; risks involve earnings volatility and competitive pressures in media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
